Recommendations for the management of herpes zoster

Clinical Infectious Diseases

Volumn 44, Issue SUPPL. 1, 2007, Pages

  Dworkin, Robert H ^a,b,w   Johnson, Robert W ^p   Breuer, Judith ^q   Gnann, John W ^d,f   Levin, Myron J ^g   Backonja, Miroslav ^h   Betts, Robert F ^b   Gershon, Anne A ^c   Haanpää, Maija L ^t   McKendrick, Michael W ^r   Nurmikko, Turo J ^s   Oaklander, Anne Louise ⁱ   Oxman, Michael N ^j   Pavan Langston, Deborah ⁱ   Petersen, Karin L ^l   Rowbotham, Michael C ^l   Schmader, Kenneth E ^m   Stacey, Brett R ⁿ   Tyring, Stephen K ^o   Van Wijck, Albert J M ^u   Wallace, Mark S ^k   Wassilew, Sawko W ^v   Whitley, Richard J ^e   more..

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d University of Alabama at Birmingham   (United States)

^e University of Alabama at Birmingham   (United States)

^f BIRMINGHAM VA MEDICAL CENTER   (United States)

^g Children's Hospital Colorado   (United States)

^h UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^k University of California   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF OREGON   (United States)

^o UNIVERSITY OF TEXAS   (United States)

^p UNIVERSITY OF BRISTOL   (United Kingdom)

^q QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^r ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^s UNIVERSITY OF LIVERPOOL   (United Kingdom)

^t HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^u UTRECHT UNIVERSITY   (Netherlands)

^v Klinikum Krefeld   (Germany)

^w UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; AMITRIPTYLINE; ANALGESIC AGENT; ANTIVIRUS AGENT; CODEINE; CORTICOSTEROID; DULOXETINE; FAMCICLOVIR; FLUOROPYRIMIDINE; FLUOROURACIL; GABAPENTIN; LOCAL ANESTHETIC AGENT; METHYLPREDNISOLONE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE; OXYCODONE; PARACETAMOL; PLACEBO; PREDNISOLONE; PREDNISONE; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALACICLOVIR; VENLAFAXINE;

BLURRED VISION; BONE MARROW SUPPRESSION; BREAST FEEDING; CANCER PATIENT; CHRONIC PAIN; CLINICAL PRACTICE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIFFERENTIAL DIAGNOSIS; DISEASE TRANSMISSION; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG INTERMITTENT THERAPY; EDEMA; GASTROINTESTINAL SYMPTOM; GERIATRIC PATIENT; GRANULOCYTOSIS; HEADACHE; HEART DEATH; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; KIDNEY FAILURE; LABORATORY TEST; META ANALYSIS; MOOD CHANGE; MYELITIS; NAUSEA; ORGAN TRANSPLANTATION; ORTHOSTATIC HYPOTENSION; PATHOGENESIS; PATIENT EDUCATION; PERIPHERAL EDEMA; POLYMERASE CHAIN REACTION; POSTHERPETIC NEURALGIA; PRACTICE GUIDELINE; PREGNANT WOMAN; PRIORITY JOURNAL; PRURITUS; REPEATED DRUG DOSE; RETINITIS; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; STROKE; SUDDEN DEATH; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URINE RETENTION; VARICELLA ZOSTER VIRUS; VIRUS DETECTION; VIRUS ENCEPHALITIS; VIRUS INFECTION; VIRUS REACTIVATION; VOMITING; WEIGHT GAIN; XEROSTOMIA;

2-AMINOPURINE; ACYCLOVIR; ANALGESICS; ANTI-INFLAMMATORY AGENTS; ANTIVIRAL AGENTS; BROMODEOXYURIDINE; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; VALINE;

EID: 33845634835     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/510206     Document Type: Review

References (243)

1. Gnann JW Jr, Whitley RJ. Herpes zoster. N Engl J Med 2002; 347: 340-6.
2. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, AK H. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2004; 63:959-65.
3. Hempenstall K, Nurmikko TJ, Johnson RW, A'Hern RP, Rice AS. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2005;2:e164.
4. + T lymphocytes that express activation, memory, and skin homing markers. J Virol 2002; 76:11425-33.
5. Ku CC, Besser J, Abendroth A, Grose C, Arvin AM. Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model. J Virol 2005; 79:2651-8.
6. Ku CC, Zerboni L, Ito H, Graham BS, Wallace M, Arvin AM. Varicella-zoster virus transfer to skin by T cells and modulation of viral replication by epidermal cell interferon-α. J Exp Med 2004; 200:917-25.
7. Chen JJ, Gershon AA, Li ZS, Lungu O, Gershon MD. Latent and lytic infection of isolated guinea pig enteric ganglia by varicella zoster virus. J Med Virol 2003;70(Suppl 1):S71-8.
8. Gershon AA, Sherman DL, Zhu Z, Gabel CA, Ambron RT, Gershon MD. Intracellular transport of newly synthesised varicella-zoster virus: final envelopment in the trans-Golgi network. J Virol 1994;68: 6372-90.
9. Cole NL, Grose C. Membrane fusion mediated by herpesvirus glycoproteins: the paradigm of varicella-zoster virus. Rev Med Virol 2003; 13:207-22.
10. Wang, ZH, Gershon MD, Lungu O, Zhu Z, Gershon AA. Trafficking of varicella-zoster virus glycoprotein gI: T(338)-dependent retention in the trans-Golgi network, secretion, and mannose 6-phosphate-inhibitable uptake of the ectodomain. J Virol 2000; 74:6600-13.
11. Dahms NM, Lobel P, Kornfeld S. Mannose 6-phosphate receptors and lysosomal enzyme targeting. J Biol Chem 1989; 264:12115-8.
12. Westlund B, Dahms NM, Kornfeld S. The bovine mannose 6-phosphate/insulin- like growth factor II receptor: localization of mannose 6-phosphate binding sites to domains 1-3 and 7-11 of the extracytoplasmic region. J Biol Chem 1991; 266:23233-9.
13. Chen JJ, Zhu Z, Gershon AA, Gershon MD. Mannose 6-phosphate receptor dependence of varicella zoster virus infection in vitro and in the epidermis during varicella and zoster. Cell 2004; 119:915-26.
14. Lungu O, Annunziato PW, Gershon A, et al. Reactivated and latent varicella-zoster virus in human dorsal root ganglia. Proc Natl Acad Sci U S A 1995; 92:10980-4.
15. Cohrs RJ, Barbour M, Gilden DH. Varicella-zoster virus (VZV) transcription during latency in human ganglia: detection of transcripts mapping to genes 21, 29, 62, and 63 in a cDNA library enriched for VZV RNA. J Virol 1996; 70:2789-96.
16. Kennedy PG, Grinfeld E, Bell JE. Varicella-zoster virus gene expression in latently infected and explanted human ganglia. J Virol 2000; 74: 11893-8.
17. Cohrs RJ, Gilden DH, Kinchington RR, Grinfeld E, Kennedy PG. Varicella-zoster virus gene 66 transcription and translation in latently infected human ganglia. J Virol 2003; 77:6660-5.
18. Zerboni L, Ku CC, Jones CD, Zehnder JL, Arvin AM. Varicella-zoster virus infection of human dorsal root ganglia in vivo. Proc Natl Acad Sci U S A 2005; 102:6490-5.
19. Cohrs RJ, Randall J, Smith J, et al. Analysis of individual human trigeminal ganglia for latent herpes simplex virus type 1 and varicella-zoster virus nucleic acids using real-time PCR. J Virol 2000; 74: 11464-71.
20. Levin MJ, Cai GY, Manchak MD, Pizer Ll. Varicella-zoster virus DNA in cells isolated from human trigeminal ganglia. J Virol 2003; 77: 6979-87.
21. Wang K, Lau TY, Morales M, Mont EK, Straus SE. Laser-capture microdissection: refining estimates of the quantity and distribution of latent herpes simplex virus 1 and varicella-zoster virus DNA in human trigeminal ganglia at the single-cell level. J Virol 2005; 79: 14079-87.
22. Lungu O, Panagiotidis CA, Annunziato PW, Gershon AA, Silverstein SJ. Aberrant intracellular localization of varicella-zoster virus regulatory proteins during latency. Proc Natl Acad Sci U S A 1998; 95: 7080-5.
23. Grinfeld E, Kennedy PG. Translation of varicella-zoster virus genes during human ganglionic latency. Virus Genes 2004; 29:317-9.
24. Hayward AR, Herberger M. Lymphocyte responses to varicella zoster virus in the elderly. J Clin Immunol 1987; 7:174-8.
25. Arvin AM, Koropchak CM, Wittek AE. Immunologic evidence of reinfection varicella-zoster virus. J Infect Dis 1983; 148:200-5.
26. Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002; 20:2500-7.
27. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002; 360:678-82.
28. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271-84.
29. Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect 2000; 125:651-69.
30. Wreghitt TG, Whipp J, Redpath C, Hollingworth W. An analysis of infection control of varicella-zoster virus infections in Addenbrooke's Hospital Cambridge over a 5-year period, 1987-92. Epidemiol Infect 1996; 117:165-71.
31. Seward J. Epidemiology of varicella. In: Arvin AM, Gershon AA, eds. Varicella-zoster virus: virology and clinical management. Cambridge: Cambridge University Press, 2000:187-205.
32. Hope-Simpson RE. The nature of herpes zoster, a long-term study and a new hypothesis. Proc R Soc Med 1965; 58:9-20.
33. Ragozzino MW, Melton LJ III, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine 1982; 61:310-6.
34. Donahue JG, Choo PW, Manson J, Platt R. The incidence of herpes zoster. Arch Intern Med 1995; 155:1605-9.
35. Schmader K, George LK, Hamilton JD. Racial differences in the occurrence of herpes zoster. J Infect Dis 1995; 171:701-4.
36. Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ 2000; 321:794-6.
37. Mullooly JP, Riedlinger K, Chun C, Weinmann S, Houston H. Incidence of herpes zoster, 1997-2002. Epidemiol Infect 2005; 133: 245-53.
38. Yih WK, Brooks DR, Lett SM, et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health 2005; 5: 68.
39. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005; 20:748-53.
40. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005; 191:2002-7.
41. Schuette MC, Hethcote HW. Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles. Bull Math Biol 1999; 61:1031-64.
42. Edmunds J, Brisson M. The effect of vaccination on the epidemiology of varicella zoster virus. J Infect 2002; 44:211-9.
43. Klein NP, Holmes TH, Sharp MA, et al. Variability and gender differences in memory T cell immunity to varicella-zoster virus in healthy adults. Vaccine 2006;24:5913-8.
44. Head H, Campbell AW. The pathology of herpes zoster and its bearing on sensory localization. Brain 1900; 23:353-523.
45. Denny-Brown D, Adams RD, Fitzgerald PJ. Pathologic features of herpes zoster: a note on geniculate herpes. Arch Neurol Psychiatry 1944; 51:216-31.
46. Liddell K. Post-herpetic pruritus. BMJ 1974; 4:165.
47. Haanpää M, Häkkinen V, Nurmikko T. Motor involvement in acute herpes zoster. Muscle Nerve 1997; 20:1433-8.
48. Furuta Y, Fukuda S, Suzuki S, Takasu T, Inuyaraa Y, Nagashiraa K. Detection of varicella-zoster virus DNA in patients with acute peripheral facial palsy by the polymerase chain reaction, and its use for early diagnosis of zoster sine herpete. J Med Virol 1997; 52:316-9.
49. Murakami S, Honda N, Mizobuchi M, Nakashiro Y, Hato N, Gyo K. Rapid diagnosis of varicella zoster virus infection in acute facial palsy. Neurology 1998; 51:1202-5.
50. Stjernquist-Desatnik A, Skoog E, Aurelius E. Detection of herpes simplex and varicella-zoster viruses in patients with Bell's palsy by the polymerase chain reaction technique. Ann Otol Rhinol Laryngol 2006; 115:306-11.
51. Grogan PM, Gronseth GS. Practice parameter: steroids, acyclovir, and surgery for Bell's palsy (an evidence-based review). Neurology 2001; 56:830-6.
52. Allen D, Dunn L. Aciclovir or valaciclovir for Bell's palsy (idiopathic facial paralysis) [review]. Cochrane Database Syst Rev 2004; 3: CD001869.
53. Holland NJ, Weiner M. Recent developments in Bell's palsy. BMJ 2004; 329:553-7.
54. Salinas RA, Alvarez G, Ferreira J. Corticosteroids for Bell's palsy (idiopathic facial paralysis). Cochrane Database Syst Rev 2004; 4: CD001942.
55. Piercy J. Bell's palsy. BMJ 2005; 330:1374.
56. Sweeney CJ, Gilden DH. Ramsay Hunt syndrome. J Neurol Neurosurg Psychiatry 2001; 71:149-54.
57. Grose C, Bonthius D, Afifi AK. Chickenpox and the geniculate ganglion: facial nerve palsy, Ramsay Hunt syndrome and acyclovir treatment. Pediatr Infect Dis J 2002; 21:615-7.
58. Osaki Y, Matsubayashi K, Okumiya K, Wada T, Doi Y. Polyneuritis cranialis due to varicella-zoster virus in the absence of rash. Neurology 1995; 45:2293.
59. Jude E, Chakraborty A. Left sixth cranial nerve palsy with herpes zoster ophthalmicus. N Engl J Med 2005;353:e14.
60. Haanpää M, Dastidar P, Weinberg A, et al. CSF and MRI findings in patients with acute herpes zoster. Neurology 1998; 51:1405-11.
61. Echevarria JM, Casas I, Martinez-Martin P. Infections of the nervous system caused by varicella-zoster virus: a review. Intervirology 1997; 40:72-84.
62. Easton HG. Zoster sine herpete causing acute trigeminal neuralgia. Lancet 1970; 2:1065-6.
63. Barrett AP, Katelaris CH, Morris JG, Schifter M. Zoster sine herpete of the trigeminal nerve. Oral Surg Oral Med Oral Pathol 1993; 75: 173-5.
64. Gilden DH, Wright RR, Schneck SA, Gwaltney JM, Mahalingam R. Zoster sine herpete, a clinical variant. Ann Neurol 1994; 35:530-3.
65. Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 2000; 342:635-45.
66. McKendrick MW, Care CC, Kudesia G, Bates CJ, Oxley MK, Eley A. Is VZV reactivation a common cause of unexplained unilateral pain? Results of a prospective study of 57 patients. J Infect 1999; 39:209-12.
67. Guess HA, Broughton DD, Melton LJ, Kurland LT. Epidemiology of herpes zoster in children and adolescents: a population-based study. Pediatrics 1985; 76:512-7.
68. Petursson G, Helgason S, Gudmundsson S, Sigurdsson JA. Herpes zoster in children and adolescents. Pediatr Infect Dis J 1998; 17:905-8.
69. Kalman CM, Laskin OL. Herpes zoster and zosteriform herpes simplex infections in immunocompetent adults. Am J Med 1986; 81:775-8.
70. Rübben A, Baron JM, Grussendorf-Conen EI. Routine detection of herpes simplex virus and varicella zoster virus by polymerase chain reaction reveals that initial herpes zoster is frequently misdiagnosed as herpes simplex. Br J Dermatol 1997; 137:259-61.
71. Nahass GT, Goldstein BA, Zhu WY, Serfling U, Penneys NS, Leonardi CL. Comparison of Tzanck smear, viral culture, and DNA diagnostic methods in detection of herpes simplex and varicella-zoster infection. JAMA 1992; 268:2541-4.
72. Dahl H, Marcoccia J, Line A. Antigen detection: the method of choice in comparison with virus isolation and serology for laboratory diagnosis of herpes zoster in human immunodeficiency virus-infected patients. J Clin Microbiol 1997; 35:347-9.
73. Jemsek J, Greenberg SB, Taber L, Harvey D, Gershon A, Couch RB. Herpes zoster-associated encephalitis: clinicopathologic report of 12 cases and review of the literature. Medicine 1983; 62:81-97.
74. Hughes BA, Kimmell DW, Aksamit AJ. Herpes-zoster associated meningoencephalitis in patients with systemic cancer. Mayo Clin Proc 1993; 68:652-5.
75. De La Blanchardiere A, Rozenberg F, Caumes E, et al. Neurological complications of varicella-zoster virus infection in adults with human immunodeficiency virus infection. Scand J Infect Dis 2000; 32:263-9.
76. Amlie-Lefond C, Kleinschmidt-Demasters BK, Mahalingam R, Davis LE, Gilden DH. The vasculopathy of varicella-zoster virus encephalitis. Ann Neurol 1995; 37:784-90.
77. Aygun N, Finelli DA, Rodgers MS, Rhodes RH. Multifocal varicella-zoster virus leukoencephalitis in a patient with AIDS: MR findings. Am J Neuroradiol 1998; 19:1897-9.
78. Kleinschmidt-DeMasters BK, Amlie-Lefond C, Gilden DH. The patterns of varicella zoster virus encephalitis. Hum Pathol 1996;27: 927-38.
79. Poscher ME. Successful treatment of varicella-zoster virus meningoencephalitis in patients with AIDS: report of 4 cases and review. AIDS 1994;8:1115-7.
80. Verghese A, Sugan AM. Herpes zoster ophthalmicus and granulomalous angiitis: an ill-appreciated cause of stroke. J Am Geriatr Soc 1986; 34:309-12.
81. Moriuchi H, Rodriguez W. Role of varicella-zoster virus in stroke syndromes. Pediatr Infect Dis J 2000; 19:648-53.
82. Eidelberg D, Sotrel A, Horoupian DS, Neumann PE, Pumarold-Sune T, Price RW. Thrombotic cerebral vasculopathy associated with herpes zoster. Ann Neurol 1986; 19:7-14.
83. Reshef E, Greenberg SB, Jankovic J. Herpes zoster ophthalmicus followed by contralateral hemiparesis: report of two cases and review of literature. J Neurol Neurosurg Psychiatry 1985; 48:122-7.
84. Gilden DH, Beinlick BR, Rubinstein EM, et al. Varicella-zoster virus myelitis: an expanding spectrum. Neurology 1994; 44:1818-23.
85. Devinsky O, Cho ES, Petito CK, Price RW Herpes zoster myelitis. Brain 1991; 114:1181-96.
86. Heller HM, Carnevale NT, Steigbigel RT. Varicella zoster virus transverse myelitis without cutaneous rash. Am J Med 1990; 88:550-1.
87. Grant AD, Fox JD, Brink NS, Miller RF. Detection of varicella-zoster virus DNA using the polymerase chain reaction in an immunocompromised patient with transverse myelitis secondary to herpes zoster. Genitourin Med 1993; 69:273-5.
88. Manian FA, Kindred M, Fulling KH. Chronic varicella-zoster virus myelitis without cutaneous eruption in a patient with AIDS: report of a fatal case. Clin Infect Dis 1995; 21:986-8.
89. Hwang YM, Lee BI, Chung JW, Ahn JH, Kim KW, Kim DI. A case of herpes zoster myelitis: positive magnetic resonance imaging finding. Eur Neurol 1991; 31:164-7.
90. Engstrom RE, Holland GN, Maryolis TP, et al. The progressive outer retinal necrosis syndrome: a variant of necrotizing herpetic retinopathy in patients with AIDS. Ophthalmology 1994; 101:1488-502.
91. Moorthy RS, Weinberg DV, Teich SA, et al. Management of varicella zoster virus retinitis in AIDS. Br J Ophthalmol 1997; 81:189-94.
92. Ormerod LD, Larkin JA, Margo CA, et al. Rapidly progressive herpetic retinal necrosis: a blinding disease characteristic of advanced AIDS. Clin Infect Dis 1998; 26:34-45.
93. Batisse D, Eliaszewicz M, Zazoan L, Baudrimont M, Pialoux G, Dupont B. Acute retinal necrosis in the course of AIDS: study of 26 cases. AIDS 1996; 10:55-60.
94. Kashiwase M, Sata T, Yamauchi Y, et al. Progressive outer retinal necrosis caused by herpes simplex virus type 1 in a patient with acquired immunodeficiency syndrome. Ophthalmology 2000; 107: 790-4.
95. Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain 1996; 67:241-51.
96. Arani RB, Soong SJ, Weiss HL, et al. Phase specific analysis of herpes zoster associated pain data: a new statistical approach. Stat Med 2001; 20:2429-39.
97. Desmond RA, Weiss HL, Arani RB, et al. Clinical application for change-point analysis of herpes zoster pain. J Pain Symptom Manage 2002; 23:510-6.
98. Jung BF, Johnson RW, Griffin DRJ, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004; 62:1545-51.
99. Bowsher D. The lifetime occurrence of herpes zoster and prevalence of postherpetic neuralgia: a retrospective survey in an elderly population. Eur J Pain 1999; 3:335-42.
100. McKendrick MW, Wood MJ. Acyclovir and post-herpetic neuralgia: two other participating centres report different results. BMJ 1995; 310:1005.
101. Meister W, Neiß A, Gross G, et al. A prognostic score for postherpetic neuralgia in ambulatory patients. Infection 1998; 26:359-63.
102. Whitley RJ, Weiss HL, Soong SJ, Gnann JW. Herpes zoster: risk categories for persistent pain. J Infect Dis 1999; 179:9-15.
103. Dworkin RH, Schmader KE. The epidemiology and natural history of herpes zoster and postherpetic neuralgia. In: Watson CPN, Gershon AA, eds. Herpes zoster and postherpetic neuralgia. 2nd ed. New York: Elsevier Press, 2001:39-64.
104. Fields HL, Rowbotham M, Baron R. Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol Dis 1998; 5:209-27.
105. Rowbotham MC, Baron R, Petersen KL, Fields HL. Spectrum of pain mechanisms contributing to PHN. In: Watson CPN, Gershon AA, eds. Herpes zoster and postherpetic neuralgia. 2nd ed. New York: Elsevier Press, 2001:183-95.
106. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004; 140: 441-51.
107. Petersen KL, Fields HL, Brennum J, Sandroni P, Rowbotham MC. Capsaicin evoked pain and allodynia in post-herpetic neuralgia. Pain 2000; 88:125-33.
108. Watson CPN, Deck JH, Morshead C, van der Kooy D, Evans RJ. Post-herpetic neuralgia: further post-mortem studies of cases with and without pain. Pain 1991; 44:105-17.
109. Rowbotham MC, Yosipovitch G, Connolly MK, Finlay D, Forde G, Fields HL. Cutaneous innervation density in the allodynk form of postherpetic neuralgia. Neurobiol Dis 1996; 3:205-14.
110. Oaklander AL, Romans K, Horasek S, Stocks A, Hauer P, Meyer RA. Unilateral postherpetic neuralgia is associated with bilateral sensory neuron damage. Ann Neurol 1998; 44:789-95.
111. Gilron I, Bailey JM, Dongsheng T, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005; 352:1324-34.
112. Surman OS, Flynn T, Schooley RT, et al. A double-blind, placebo-controlled study of oral acyclovir in postherpetic neuralgia. Psychosomatics 1990; 31:287-92.
113. Acosta EP, Balfour HH Jr. Acyclovir for treatment of postherpetic neuralgia: efficacy and pharmacokinetics. Antimicrob Agents Chemother 2001; 45:2771-4.
114. Gilden DH, Cohrs RJ, Mahalingam R. VZV vasculopathy and postherpetic neuralgia: progress and perspective on antiviral therapy. Neurology 2005; 64:21-5.
115. Quan D, Hammack BN, Kittelson J, Gilden DH. Improvement of postherpetic neuralgia after treatment with intravenous acyclovir followed by oral valacyclovir. Arch Neurol 2006; 63:940-2.
116. Oaklander AL, Bowsher D, Galer BS, Haanpää ML, Jensen MP. Herpes zoster itch: preliminary epidemiologic data. J Pain 2003; 4:338-43.
117. Oaklander AL, Cohen SP, Raju SV. Intractable postherpetic itch and cutaneous deafferentation after facial shingles. Pain 2002; 96:9-12.
118. Lancaster T, Silagy C, Gray S. Primary care management of acute herpes zoster: systematic review of evidence from randomized controlled trials. Br J Gen Pract 1995; 45:39-45.
119. Wood MJ, Kay R, Dworkin RH, Soong SJ, Whitley RJ. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996; 22: 341-7.
120. Jackson JL, Gibbons R, Meyer G, Inouye L. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia: a meta-analysis. Arch Intern Med 1997; 157:909-12.
121. Alper BS, Lewis PR. Does treatment of acute herpes zoster prevent or shorten postherpetic neuralgia? A systematic review of the literature. J Fam Pract 2000; 49:255-64.
122. British Society for the Study of Infection. Guidelines for the management of shingles: report of a working group of the British Society for the Study of Infection. J Infect 1995; 30:193-200.
123. Peyramond D, Chidiac C, Lucht F, et al. Management of infections due to the varicella-zoster virus. Eur J Dermatol 1998; 8:397-402.
124. Johnson R, Patrick D, eds. Improving the management of varicella, herpes zoster and zoster-associated pain. Recommendations from the IHMF Management Strategies Workshop. International Herpes Management Forum, 2002. Available at: http://www.ihmf.org/library/monograph/m_11.pdf. Accessed 17 July 2006.
125. Gross G, Schöfer H, Wassilew S, et al. Herpes zoster guideline of the German Dermatology Society (DDG). J Clin Virol 2003; 26:277-89.
126. Cook DJ, Greengold NL, Ellrodt AG, Weingarten SR. The relation between systematic reviews and practice guidelines. Ann Intern Med 1997; 127:210-6.
127. Slavin RE. Best evidence synthesis: an intelligent alternative to meta-analysis. J Clin Epidemiol 1995; 48:9-18.
128. Rychetnik L, Hawe P, Waters E, Barratt A, Frommer M. A glossary for evidence based public health. J Epidemiol Community Health 2004; 58:538-45.
129. Coplan PM, Schmader K, Nikas A, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the Brief Pain Inventory. J Pain 2004; 5:344-56.
130. McKendrick MW, McGill JI, White JE, Wood MJ. Oral acyclovir in acute herpes zoster. BMJ 1986; 293:1529-32.
131. McKendrick MW, McGill JI, Wood MJ. Lack of effect of acyclovir on postherpetic neuralgia. BMJ 1989; 298:431.
132. Huff JC, Bean B, Balfour HH Jr, et al. Therapy of herpes zoster with oral acyclovir. Am J Med 1988; 85(Suppl 2A):84-9.
133. Huff JC, Drucker JL, Clemmer A, et al. Effect of oral acyclovir on pain resolution in herpes zoster: a reanalysis. J Med Virol 1993; Suppl 1:93-6.
134. Wood MJ, Ogan PH, McKendrick MW, Care CD, McGill JI, Webb EM. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med 1988; 85(Suppl 2A):79-83.
135. Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J 1989; 102:93-5.
136. Harding SP, Porter SM. Oral acyclovir in herpes zoster ophthalmicus. Curr Eye Res 1991; 10(Suppl):177-82.
137. Degreef H. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents 1994; 4:241-6.
138. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123:89-96.
139. Dworkin RH, Boon RJ, Griffin DR, Phung D. Postherpetic neuralgia: impact of famciclovir, age, rash severity and acute pain in herpes zoster patients. J Infect Dis 1998; 178(Suppl 1):S76-80.
140. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995; 39:1546-53.
141. Shen MC, Lin HH, Lee SSJ, Chen YS, Chiang PC, Liu YC. Double-blind, randomized, acyclovir-controlled, parallel-group trial comparing the safety and efficacy of famciclovir and acyclovir in patients with uncomplicated herpes zoster. J Microbiol Immunol Infect 2004; 37:75-81.
142. Lin WR, Lin HH, Lee SSJ, et al. Comparative study of the efficacy and safety of valaciclovir versus acyclovir in the treatment of herpes zoster. J Microbiol Immunol Infect 2001; 34:138-42.
143. Shafran SD, Tyring SK, Ashton R, et al. Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol 2004; 29:248-53.
144. Wassilew SW, Wutzler P. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. Antiviral Res 2003; 59:49-56.
145. Wassilew SW, Wutzler P. Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on postherpetic neuralgia. Antiviral Res 2003; 59:57-60.
146. Wassilew SW. Brivudin compared with famciclovir in the treatment of herpes zoster: effects in acute disease and chronic pain in immunocompetent patients. A randomized, double-blind, multinational study. J Eur Acad Dermatol Venereol 2005; 19:47-55.
147. Crooks RJ, Jones DA, Fiddian AP. Zoster-associated chronic pain: an overview of clinical trials with acyclovir. Scand J Infect Dis Suppl 1991; 78:62-8.
148. Whitley RJ, Weiss H, Gnann JW Jr, et al. Acyclovir with and without prednisone for the treatment of herpes zoster: a randomized, placebo-controlled trial. Ann Intern Med 1996; 125:376-83.
149. Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000; 9:863-9.
150. Wood MJ, Shukla S, Fiddian AP, Crooks RJ. Treatment of acute herpes zoster: effect of early (<48 h) versus late (48-72 h) therapy with acyclovir and valaciclovir on prolonged pain. J Infect Dis 1998; 178(Suppl 1):S81-4.
151. Decroix J, Partsch H, Gonzalez R, et al. Factors influencing pain outcome in herpes zoster: an observational study with valaciclovir. J Eur Acad Dermatol Venereol 2000; 14:23-33.
152. Kurokawa I, Kumano K, Murakawa K. Clinical correlates of prolonged pain in Japanese patients with herpes zoster. J Int Med Res 2002; 30: 56-65.
153. Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994; 330:896-900.
154. Söltz-Szöts J, Tyring S, Andersen PL, et al. A randomized controlled trial of acyclovir versus netivudine for treatment of herpes zoster. J Antimicrob Chemother 1998; 41:549-56.
155. Dworkin RH, Schmader KE. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis 2003; 36:877-82.
156. McQuay HJ, Tramèr M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain 1996; 68:217-27.
157. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005; 118:289-305.
158. Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 1997; 13:327-31.
159. Dworkin RH. Prevention of postherpetic neuralgia. Lancet 1999; 353: 1636-7.
160. Roose SP, Laghrissi-Thode F, Kennedy JS, et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998; 279:287-91.
161. Ray WA, Meredith S, Thapa BP, Hall K, Murray KT. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004; 75:234-41.
162. Dworkin RH, Backonja M, Rowbothara MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003; 60:1524-34.
163. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004; 110:697-706.
164. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116: 109-18.
165. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003; 349:1943-53.
166. Eisenberg E, McNichol ED, Carr DB. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA 2005; 293:3043-52.
167. Watson CPN, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998; 50: 1837-41.
168. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002; 59:1015-21.
169. Dworkin RH. Strategies for the prevention of neuropathic pain. In: Program and abstracts of Expanding Vistas in Neuropathic Pain, an official satellite of the 11th World Congress on Pain (Uluru, Australia). Seattle: International Association for the Study of Pain Neuropathic Pain Special Interest Group, 2005:39.
170. Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain 2003; 104:323-31.
171. Rowbotham MC, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280:1837-42.
172. Rice ASC, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001; 94:215-24.
173. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003; 60:1274-83.
174. Sabatowski R, Gálvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 2004; 109:26-35.
175. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005; 115:254-63.
176. van Seventer R, Feister HA, Young JP Jr, Stoker M, Versavel M, Rigaudy L. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin 2006; 22:375-84.
177. Berry JD, Petersen KL. A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster. Neurology 2005; 65:444-7.
178. Brentjens MH, Torres G, He J, Lee PC, Tyring SK. Reduction of postherpetic neuralgia in herpes zoster: a study of the effects of gabapentin with valacyclovir during acute zoster outbreaks. Presented at: Annual Meeting of the American Academy of Dermatology (San Francisco, March 2003).
179. Dahl JB, Mathiesen O, Møiniche S. 'Protective premedication:' an option with gabapentin and related drugs? A review of gabapentin and pregabalin in the treatment of post-operative pain. Acta Anaesthesiol Scand 2004; 48:1130-6.
180. Kuraishi Y, Takasaki I, Nojima H, Shiraki K, Takahata H. Effects of the suppression of acute pain by gabapentin and amitriptyline on the incidence of delayed postherpetic pain in mice. Life Sci 2004; 74: 2619-26.
181. Rowbotham MC, Young JP Jr, Sharma U. Pregabalin significantly reduces neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia by day 3 of treatment. In: Program and abstracts of Neuropathic Pain: Changing Paradigms in Diagnosis and Treatment (Madrid). Seattle: International Association for the Study of Pain Neuropathic Pain Special Interest Group, 2004:48.
182. Wu CL, Marsh A, Dworkin RH. The role of sympathetic nerve blocks in herpes zoster and postherpetic neuralgia. Pain 2000; 87:121-9.
183. Kumar V, Krone K, Mathieu A. Neuraxial and sympathetic blocks in herpes zoster and postherpetic neuralgia: an appraisal of current evidence. Reg Anesth Pain Med 2004; 29:454-61.
184. Opstelten W, van Wijck AJM, Stoiker RJ. Interventions to prevent postherpetic neuralgia: cutaneous and percutaneous techniques. Pain 2004; 107:202-6.
185. van Wijck AJM, Opstelten W, Moons KGM, et al. The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial. Lancet 2006; 367:219-24.
186. Pasqualucci A, Pasqualucci V, Galla F, et al. Prevention of post-herpetic neuralgia: acyclovir and prednisolone versus epidural local anesthetic and methylprednislone. Acta Anaesthesiol Scand 2000; 44: 910-8.
187. Manabe H, Dan K, Hirata K, et al. Optimum pain relief with continuous epidural infusion of local anesthetics shortens the duration of zoster-associated pain. Clin J Pain 2004; 20:302-8.
188. Hügler P, Siebrecht P, Hoffmann K, et al. Prevention of postherpetic neuralgia with varicella-zoster hyperimmune globulin. Eur J Pain 2002; 6:435-45.
189. Ahmed HE, Craig WF, White PF, et al. Percutaneous electrical nerve stimulation: an alternative to antiviral drugs for acute herpes zoster. Anesth Analg 1998; 87:911-4.
190. Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 2004; 328:991-4.
191. Haanpää M, Laippala P, Nurmikko T. Allodynia and pinprick hypesthesia in acute herpes zoster, and the development of postherpetic neuralgia. J Pain Symptom Manage 2000; 20:50-8.
192. Watson CPN, Vernich L, Chipman M, Reed K. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology 1998; 51:1166-71.
193. Serota FT, Starr SE, Bryan CK, Koch PA, Plotkin SA, August CS. Acyclovir treatment of herpes zoster infections use in children undergoing bone marrow transplant. JAMA 1982; 247:2132-6.
194. Balfour HH, Bean B, Laskin OL, et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 1983; 308:1448-53.
195. Meyers JD, Wade JC, Shepp DH, Newton B. Acyclovir treatment of varicella-zoster virus infection in the compromised host. Transplantation 1984; 37:571-4.
196. Shepp DH, Dandliker PS, Meyers JD. Treatment of varicella-zoster infection in severely immunocompromised patients: a randomized comparison of acyclovir and vidarabine. N Engl J Med 1986; 314: 208-12.
197. Ljungman P, Lonnqvist B, Ringden O, Skinhoj P, Gahrton G. A randomized trial of oral versus intravenous acyclovir for treatment of herpes zoster in bone marrow transplant recipients. Bone Marrow Transplant 1989; 4:613-5.
198. Tyring S, Belanger R, Bezwoda W, Ljungman P, Boon R, Saltzman RL. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest 2001; 19:13-22.
199. Brentjens MH, Torres G, He J, Lee PC, Tyring SK. A double-blind randomized study of the use of 2 grams vs. 1 gram valacyclovir TlD for 7 days in the treatment of acute herpes zoster in immunocompromised individuals. Presented at: Annual Meeting of the American Academy of Dermatology (San Francisco, March 2003).
200. Wutzler P, de Clercq E, Wutke K, Färber I. Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomized double-blind trial. J Med Virol 1995; 46:252-7.
201. Walton RC, Reed KL Herpes zoster ophthalmicus following bone marrow transplantation in children. Bone Marrow Transplant 1999; 23:1317-20.
202. Bodsworth NJ, Boag F, Burdge D, et al. Evaluation of sorivudine (BV-araU) versus acyclovir in the treatment of acute localized herpes zoster in human immunodeficiency virus-infected adults. J Infect Dis 1997; 176:103-11.
203. Gnann JW Jr, Crumpacker CS, Lalezari JP, et al. Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Antimicrob Agents Chemother 1998; 42: 1139-45.
204. Sullivan M, Skiest D, Signs D, Young C. Famciclovir in the management of acute herpes zoster in HIV+ patients. Presented at: Fourth Conference on Retroviruses and Opportunistic Infections (Washington, DC, 22-26 January 1997).
205. Cobo LM. Corneal complications of herpes zoster ophthalmicus. Cornea 1988; 7:50-6.
206. Holland GN. Acquired immune deficiency syndrome and ophthalmology: the first decade. Am J Ophthalmol 1992; 114:86-95.
207. Mahalingam R, Wellish M, Wolf W, et al. Latent varicella-zoster viral DNA in human trigeminal and thoracic ganglia. N Engl J Med 1990; 323:627-31.
208. Kurland L. Descriptive epidemiology of selected neurological and myopathic disorders with particular reference to a survey in Rochester, Minnesota. J Chronic Dis 1958; 8:378-418.
209. Ragozzino MW, Melton LF III, Kurland LT. Population-based study of herpes zoster and its sequelae. Medicine 1982; 61:310-6.
210. Liesegang TJ. The varicella-zoster virus: systemic and ocular features. J Am Acad Dermatol 1984; 11:165-91.
211. Weller TH. Varicella-zoster virus: history, perspectives, and evolving concerns. Neurology 1995; 45(Suppl 8):S9-10.
212. Oxman MN, Williams HM, Levin MJ, et al. Efficacy of zoster vaccine according to dermatome region. Presented at: 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC, 16-19 December 2005).
213. Miserocchi E, Waheed NK, Dios E, et al. Visual outcome in herpes simplex virus and varicella zoster virus uveitis: a clinical evaluation and comparison. Ophthalmology 2002; 109:1532-7.
214. Womack LW, Liesegang TJ. Complications of herpes zoster ophthalmicus. Arch Ophthalmol 1983; 101:42-5.
215. Liesegang TJ. Corneal complications from herpes zoster ophthalmicus. Ophthalmology 1985; 92:316-24.
216. Liesegang TJ. Varicella-zoster virus eye disease. Cornea 1999; 18: 511-31.
217. Pavan-Langston D. Ophthalmic zoster. In: Watson CPN, Gershon A. Herpes zoster and postherpetic neuralgia. Amsterdam: Elsevier, 2001: 119-29.
218. Pavan-Langston D. Viral disease of the ocular anterior segment: basic science and clinical disease. In: Foster S, Azar D, Dohlman C. The Cornea. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2005: 297-397.
219. Cobo L, Foulks G, Liesegang T. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology 1986; 93:763-70.
220. Colin J, Prisant O, Cochener B, Lescale O, Rolland B, Hoang-Xuan T. Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. Ophthalmology 2000; 107:1507-11.
221. Tyring S, Engst R, Corriveau C, et al. Famciclovir for ophthalmic zoster: a randomised aciclovir controlled study. Br J Ophthalmol 2001; 85:576-81.
222. Severson EA, Baratz KH, Hodge DO, Burke JP. Herpes zoster ophthalmicus in Olmsted County, Minnesota: have systemic antivirals made a difference? Arch Ophthalmol 2003; 121:386-90.
223. Tenicela R, Lovasik D, Eaglstein W. Treatment of herpes zoster with sympathetic blocks. Clin J Pain 1985; 1:63-7.
224. Harding SP, Lipton JR, Wells JCD, Campbell JA. Relief of acute pain in herpes zoster ophthalmicus by stellate ganglion block. BMJ 1986; 292:1428.
225. Nurmikko T, Räsänen A, Häkkinen V. Clinical and neurophysiological observations on acute herpes zoster. Clin J Pain 1990; 6:284-90.
226. Johnston WH, Holland GN, Engstrom RE, Rimmer S. Recurrence of presumed varicella-zoster virus retinopathy in patients with acquired immune deficiency syndrome. Am J Ophthalmol 1993; 116:42-50.
227. Galindez OA, Sabates NR, Whitacre MW, Sabates FN. Rapidly progressive outer retinal necrosis caused by varicella zoster virus in a patient infected with human immunodeficiency virus. Clin Infect Dis 1996; 22:149-51.
228. Spaide RF, Martin DF, Teich SA, Katz A, Toth I. Successful treatment of progressive outer retinal necrosis syndrome. Retina 1996; 16:479-87.
229. Meffert SA, Kertes PJ, Lim PL, Conway MD, Peyman GA. Successful treatment of progressive outer retinal necrosis using high-dose intravitreal ganciclovir. Retina 1997; 17:560-2.
230. Perez-Blazquez E, Traspas R, Mendez MI, Montera M. Intravitreal ganciclovir treatment in progressive outer retinal necrosis. Am J Ophthalmol 1997; 124:418-21.
231. Ciulla TA, Rutledge BK, Morley MG, Duker JS. The progressive outer retinal necrosis syndrome: successful treatment with combination antiviral therapy. Ophthalmic Surg Lasers 1998; 29:198-206.
232. Scott IU, Luu KM, Davis JL. Intravitreal antivirals in the management of patients with acquired immunodeficiency syndrome with progressive outer retinal necrosis. Arch Ophthalmol 2002; 120:1219-22.
233. Schliefer K, Gumbel HO, Rockstroh JK, Spengler U. Management of progressive outer retinal necrosis with cidofovir in a human immunodeficiency virus-infected patient. Clin Infect Dis 1999; 29:684-5.
234. Zambarakji HJ, Obi AA, Mitchell SM. Successful treatment of varicella zoster virus retinitis with aggressive intravitreal and systemic antiviral therapy. Ocul Immunol Inflamm 2002; 10:41-6.
235. Palay DA, Sternberg P Jr, Davis J, et al. Decrease in the risk of bilateral acute retinal necrosis by acyclovir therapy. Am J Ophthalmol 1991; 112:250-5.
236. Wenger NS, Shekelle PG. Assessing care of vulnerable elders: ACOVE project overview. Ann Intern Med 2001; 135:642-6.
237. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci 2004; 59: 255-63.
238. Cusack BJ. Pharmacokinetics in older persons. Am J Geriatr Pharmacother 2004; 2:274-303.
239. Rochon PA, Gurwitz JH. Drug therapy. Lancet 1995; 346:32-6.
240. Weiner D, Peterson B, Lad K, McConnell E, Keefe F. Pain in nursing home residents: an exploration of prevalence, staff perspectives, and practical aspects of measurement. Clin J Pain 1999; 15:92-101.
241. Schmader KE, Twersky JT. Herpes zoster, cellulitis, and scabies. In: Yoshikawa TT, Ouslander JG, eds. Infection management for geriatrics in long-term care facilities. New York: Marcel-Dekker, 2002:283-305.
242. Reiff-Eldridge R, Heffner CR, Ephross SA, Tennis PS, White AD, Andrews EB. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am J Obstet Gynecol 2000; 182:159-63.
243. Gnann JW Jr. Varicella-zoster virus: atypical presentations and unusual complications. J Infect Dis 2002; 186(Suppl 1):S91-8.